Chemometec

"Management adopts a cautiously defensive tone — acknowledging significant revenue and EBITDA declines (-17% and -36% respectively) while attempting to frame them as expected and manageable. The CEO's statement balances honest acknowledgment of headwinds with selective optimism around new products (XM40, XM30) and gradual H2 recovery."